Synthetic method of loxoprofen sodium and intermediate compound of loxoprofen sodium

By using the methylene reaction of cyclopentanone and paraformaldehyde and Heck coupling reaction in the synthesis of loxoprofen sodium, combined with catalytic hydrogenation, the high temperature and high pressure and corrosive hydrobromic acid were successfully avoided, and the existing solutions were solved The high-quality raw materials and harsh reaction conditions in the technology have achieved low-cost and environmentally friendly synthesis of loxoprofen sodium.

CN119019242APending Publication Date: 2024-11-26XIAMEN MEDICAL COLLEGE
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202310584304.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing method of synthesis of loxoprofen sodium uses expensive 2-(4-halomethyl)phenylpropionate as the starting material, and requires high-temperature and high-pressure hydrochloric acid hydrocarboxylation reaction, resulting in equipment corrosion and wastewater generation. and the carbonization of products, high cost and is not suitable for industrial production.

Method used

Cyclopentanone and paraformaldehyde were used to form 2-methylene cyclopentanone under the action of acid, and then Heck coupling reaction was carried out with 4-halogenated phenylacetate under transition metal catalysis, and catalytic hydrogenation was obtained. Profen sodium avoids the use of high temperature and high pressure and corrosive hydrobromic acid.

Benefits of technology

It achieves easy access to raw materials, simple operation, and mild reaction conditions, avoids carbonization, reduces production costs, is suitable for industrial production, and improves environmental protection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004242717600000021
    Figure BDA0004242717600000021
  • Figure BDA0004242717600000022
    Figure BDA0004242717600000022
  • Figure BDA0004242717600000031
    Figure BDA0004242717600000031
Patent Text Reader

Abstract

The invention discloses a loxoprofen sodium synthesis method and an intermediate compound thereof. Cyclopentanone, paraformaldehyde and amine are subjected to methylenation reaction at the alpha-position of ketone under the acidic condition to generate 2-methylene cyclopentanone (II); and reacting the 4-halogenated phenylacetate (III) with methyl iodide under the action of alkali to generate 2-(4-halogenated phenyl) propionate (IV). Carrying out Heck coupling reaction on the compound (II) and the compound (IV) under the action of a transition metal catalyst, a phosphine ligand and alkali to obtain 2-(4-((5-oxocyclopent-1-alkenyl) methyl) phenyl) propionate (V), and carrying out catalytic hydrogenation on the compound (V) under the action of palladium on carbon or raney nickel to obtain 2-(4-((2-oxocyclopentyl) methyl) phenyl) propionate (VI); and salifying the compound VI in a NaOH aqueous solution to obtain loxoprofen sodium (I). The synthesis method provided by the invention has the advantages of cheap and easily available initial raw materials, short steps and simple operation, avoids the use of expensive 2-(4-halomethyl) phenylpropionic acid (ester), also avoids the use of highly corrosive hydrobromic acid for hydrolysis decarboxylation reaction, and is suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to a synthesis method of a non-steroidal anti-inflammatory drug loxoprofen sodium and an important intermediate compound thereof. Background Art

[0002] Loxoprofen Sodium (Ⅰ), chemical name is 2-[4-(2-oxocyclopentane-1-methyl)]phenylpropionic acid sodium dihydrate, is a good non-steroidal anti-inflammatory drug. The drug was first developed by Sankyo Co., Ltd. of Japan and launched in 1986 under the trade name "Loxoprofen". This variety is now the best-selling non-steroidal anti-inflammatory drug in Japan and is widely used in clinical practice. Relevant studies have shown that compared with other similar drugs, loxoprofen sodium has stronger analgesic, antipyretic and anti-inflammatory effects, fast absorption, fast onset of action, few adverse reactions, and good gastrointestinal tolerance.

[0003] The synthesis of loxoprofen sodium is generally from its free form loxoprofen. There are generally two synthetic routes, both of which use 2-(4-halomethyl)phenylpropionic acid (ester) as the starting material.

[0004] Reference 1 [China Journal of Pharmaceutical Industry, 2015, 46(08):806-808] uses 2-(4-halomethyl)phenylpropionic acid (ester) as a raw material, and condenses with 2-ethoxycarbonylcyclopentanone to generate 2-[4-(1-ethoxycarbonyl-2-oxocyclopentane-1-methyl)phenyl]propionic acid methyl ester, which is hydrolyzed and decarboxylated in hydrobromic acid to obtain loxoprofen, and then salted with sodium hydroxide solution to obtain the product loxoprofen sodium. The starting material 2-(4-halomethyl)phenylpropionic acid (ester) of this route is not easy to obtain, the preparation route is long and expensive, resulting in high route cost, and the key step: hydrolysis and decarboxylation reaction, must be carried out at high temperature and excessive hydrobromic acid, which not only causes severe corrosion to the equipment, but also produces a large amount of wastewater and waste acid. In addition, in actual research, we found that high temperature and excessive hydrobromic acid will cause obvious carbonization of the product, making the product very dark in color.

[0005]

[0006] Document 2 [J.Med.Chem.1984,27,212-216] uses N-(1-cyclopentenyl)morpholine and 2-(4-chloromethyl)phenylpropionic acid ethyl ester to undergo enamine alkylation reaction, and then obtains loxoprofen after acid hydrolysis, and then uses sodium hydroxide solution to form salt to obtain the product loxoprofen sodium. This route also needs to use 2-(4-halomethyl)phenylpropionic acid (ester) as the starting material, which is costly. In addition, the enamine alkylation reaction has a high temperature, a long time, and a low yield, making this route also unsuitable for industrial production.

[0007] Summary of the invention

[0008] The object of the present invention is to overcome the deficiencies of the prior art, provide a method for synthesizing loxoprofen sodium and an intermediate compound thereof, wherein the raw materials are readily available, the operation is simple, the reaction conditions are mild, the target compound can be obtained in a more environmentally friendly manner, and there is no carbonization phenomenon during the reaction process. In addition, the use of expensive 2-(4-halomethyl)phenylpropionic acid (ester) is avoided, and the use of highly corrosive hydrobromic acid for hydrolysis and decarboxylation reaction is also avoided.

[0009] One of the technical solutions adopted by the present invention to solve the technical problem is:

[0010] A method for synthesizing loxoprofen sodium comprises the following steps:

[0011] (a) Under the action of acid, cyclopentanone reacts with polyformaldehyde and amine at the α-position of the ketone to form 2-methylenecyclopentanone (II);

[0012] (b) 4-halogenophenylacetic acid ester (III) reacts with iodomethane in the presence of a base to generate 2-(4-halogenophenyl) propionic acid ester (IV);

[0013] (c) Compound (II) and compound (IV) undergo Heck coupling reaction in the presence of a transition metal catalyst, a phosphine ligand and a base to obtain 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propanoate (V);

[0014] (d) Compound (V) is subjected to catalytic hydrogenation to obtain 2-(4-((2-oxocyclopentyl)methyl)phenyl)propanoate (VI);

[0015] (e) Compound (VI) is salified in aqueous NaOH to obtain loxoprofen sodium (I).

[0016] The reaction involved in the present invention can be represented by the following reaction formula:

[0017]

[0018] In the above formula, R is methyl or ethyl; X is Cl, Br or I.

[0019] In step (a) of the present invention, the reaction of preparing compound (II) from cyclopentanone and paraformaldehyde requires the use of an amine, and the amine used is selected from methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, diisopropylamine, methylethylamine, methylisopropylamine, and ethylisopropylamine, wherein the amine used is preferably diisopropylamine. The amount of the amine used is preferably 1.0 to 2.0 equivalents of cyclopentanone.

[0020] In step (a) of the present invention, the reaction of preparing compound (II) from cyclopentanone and paraformaldehyde is carried out under the action of an acid, wherein the acid used is selected from acetic acid, formic acid, trifluoroacetic acid, trichloroacetic acid, sulfuric acid, and hydrochloric acid, wherein the acid used is preferably trifluoroacetic acid. The amount of the acid used is preferably 1.0 to 2.0 equivalents of cyclopentanone.

[0021] In step (a) of the present invention, the operation process of the reaction of preparing compound (II) from cyclopentanone, paraformaldehyde and amine is roughly as follows:

[0022] Add amine and solvent (such as tetrahydrofuran (THF) etc.) to the reaction flask, slowly add acid, add cyclopentanone and paraformaldehyde, and then react at 20-80°C for 1-12 hours. After the reaction is completed, filter, add sodium bicarbonate solution, separate the organic layer, wash and concentrate to obtain the crude compound (II), which can be directly used in the next step without purification.

[0023] In step (b) of the present invention, the reaction of preparing compound (IV) from compound (III) and methyl iodide is carried out under the action of a base, the base used is selected from lithium diisopropylamide, n-butyl lithium, tert-butyl lithium, wherein the base used is preferably lithium diisopropylamide (LDA). The amount of the base used is preferably 1.0 to 1.3 equivalents of compound (III).

[0024] In step (b) of the present invention, the operation process of the reaction of preparing compound (IV) from compound (III) and iodomethane is roughly as follows:

[0025] Add compound (III) and solvent (such as tetrahydrofuran (THF) etc.) to the reaction flask, cool to -78°C, add alkali dropwise, raise to 0°C after completion of the addition, react for 0.5h, cool to -78°C again, add iodomethane dropwise, then raise to 0°C to react for 1-3h. After the reaction is complete, add saturated ammonium chloride solution, separate the organic layer, wash and concentrate to obtain compound (IV), which can be directly used in the next step without purification.

[0026] In step (c) of the present invention, the reaction of preparing compound (V) from compound (II) and compound (IV) is carried out under the action of a transition metal catalyst, and the transition metal catalyst used is selected from palladium acetate, palladium chloride, tris(dibenzylideneacetone)dipalladium [Pd2(dba)3], di(dibenzylideneacetone)palladium [Pd(dba)2], tetrakis(triphenylphosphine)palladium, wherein the transition metal catalyst used is preferably palladium acetate.

[0027] In step (c) of the present invention, the reaction of preparing compound (V) from compound (II) and compound (IV) requires the addition of a phosphine ligand to stabilize the catalyst, and the phosphine ligand used is selected from triphenylphosphine, tri-tert-butylphosphine (P(t-Bu)3), tri-o-tolylphosphine, tri(2-furyl)phosphine, 1,4-bis(diphenylphosphino)butane (dppb), 1,1'-bis(diphenylphosphino)ferrocene (dppf), wherein the phosphine ligand used is preferably tri-tert-butylphosphine (P(t-Bu)3).

[0028] In step (c) of the present invention, the reaction of preparing compound (V) from compound (II) and compound (IV) requires the use of a base, and the base used is selected from triethylamine, sodium bicarbonate, sodium carbonate, pyridine, triethylamine, dicyclohexylmethylamine, diisopropylethylamine, tri-n-propylamine or sodium acetate (NaOAc), wherein the base used is preferably dicyclohexylmethylamine.

[0029] In step (c) of the present invention, the reaction of preparing compound (V) from compound (II) and compound (IV) is carried out in a suitable solvent, and the solvent used is selected from tetrahydrofuran, acetonitrile, toluene, dioxane or N,N-dimethylformamide (DMF), wherein the solvent used is preferably dioxane.

[0030] In step (c) of the present invention, the reaction temperature for preparing compound (V) from compound (II) and compound (IV) is 20-80°C.

[0031] In step (c) of the present invention, the operation process of the reaction of preparing compound (V) from compound (II) and compound (IV) is roughly as follows:

[0032] Add compound (II), compound (IV), transition metal catalyst, phosphine ligand, base and solvent into a reaction flask, replace nitrogen, and then react at 20-80°C for 1-24 hours. After the reaction, add solvent and water, separate the organic layer, wash and concentrate to obtain crude compound (V), and obtain compound (V) after column chromatography.

[0033] In step (d) of the present invention, the catalytic hydrogenation reaction of preparing compound (VI) from compound (V) is carried out under the action of a catalyst, and the catalyst used is selected from palladium carbon, platinum carbon, and Raney nickel, wherein the catalyst used is preferably palladium carbon.

[0034] In step (d) of the present invention, the reaction of preparing compound (VI) from compound (V) is carried out in a suitable solvent, and the solvent used is one or a mixture of two of the following: water, methanol, ethanol, isopropanol, tetrahydrofuran, acetic acid, wherein the solvent used is preferably ethanol.

[0035] In step (d) of the present invention, the reaction temperature for preparing compound (VI) from compound (V) is 0 to 50°C.

[0036] In step (d) of the present invention, the operation process of the reaction of preparing compound (VI) from compound (V) is roughly as follows:

[0037] Add compound (V), catalyst and solvent into the reaction flask, replace hydrogen, and react at 0-50°C under normal pressure for 1-24 hours. After the reaction is completed, filter and recover the catalyst, and concentrate the filtrate to obtain compound (VI).

[0038] In step (e) of the present invention, the reaction of preparing loxoprofen sodium (I) from compound (VI) is carried out in the presence of NaOH, which is added to the reaction system in the form of an aqueous solution. The amount of NaOH used is 1.0 equivalent of compound (VI).

[0039] In step (e) of the present invention, the reaction of preparing loxoprofen sodium (I) from compound (VI) is carried out in a mixed solvent of water and acetone, and the volume ratio of water to acetone is, for example, 1:8-12.

[0040] In step (e) of the present invention, the reaction temperature for preparing loxoprofen sodium (I) from compound (VI) is 0 to 50°C.

[0041] In step (e) of the present invention, the operation process of the reaction for preparing loxoprofen sodium (I) from compound (VI) is roughly as follows:

[0042] Add compound (VI), water and acetone to the reaction flask, slowly add aqueous NaOH solution at 0-50°C, and then react for 0.5-5 hours. After the reaction is completed, filter and dry to obtain loxoprofen sodium (I).

[0043] The second technical solution adopted by the present invention to solve its technical problem is:

[0044] The compound 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propionate is an important intermediate compound (V) in the above-mentioned route for synthesizing loxoprofen sodium, and its structural formula is shown below:

[0045] R is methyl or ethyl.

[0046] The third technical solution adopted by the present invention to solve its technical problem is:

[0047] The synthesis method of the compound 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propionate is carried out by referring to steps (a) to (c) in the above-mentioned method for synthesizing loxoprofen sodium, which will not be repeated here.

[0048] Unless otherwise specified, the equipment, reagents, processes, parameters, etc. involved in the present invention are conventional equipment, reagents, processes, parameters, etc. and are not given as embodiments.

[0049] All ranges recited herein include all point values ​​within the range.

[0050] In the present invention, the "room temperature" refers to the normal ambient temperature, which may be 10 to 30°C.

[0051] Compared with the background technology, the advantages of the present invention are:

[0052] 1. Cyclopentanone and halogenated phenylacetic acid esters (such as methyl p-bromophenylacetate, etc.) are used as substrates, and the raw materials are easily available and the cost is low;

[0053] 2. The reaction conditions in each step are mild, avoiding the use of corrosive reagents such as hydrobromic acid, which is more environmentally friendly and conducive to industrial production. DETAILED DESCRIPTION

[0054] The content of the present invention is specifically described below by embodiments:

[0055] Example 1: Synthesis of α-methylenecyclopentanone (II)

[0056] Add diisopropylamine (36.4 g, 0.36 mol) and 500 mL THF into a three-necked flask, add trifluoroacetic acid (45.1 g, 0.396 mol) dropwise at 0-20 °C, and then add cyclopentanone (30.0 g, 0.36 mol) and (HCHO) n (42.7g, 0.47mol), heated to reflux, reacted for 2h, and monitored by TLC [developing solvent PE: EA (5:1)]. After the reaction was completed, THF was removed under reduced pressure, 500mL of isopropyl ether was added, and the insoluble matter was removed by suction filtration. The filtrate was washed with 1mol / L HCl, saturated NaHCO3, and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 28.1g of yellow-green liquid 2-methylenecyclopentanone (α-methylenecyclopentanone), with a yield of 82.1%.

[0057] Example 2: Synthesis of methyl 2-(4-bromophenyl)acetate (IV)

[0058] A THF (50 mL) dried solution of methyl 4-bromophenylacetate (10.0 g, 43.65 mmol) was placed in dry ice ethanol and cooled to -78°C under N2. 2M LDA (22.0 mL, 44.0 mmol) was slowly added at -78°C, and the resulting mixture was stirred at 0°C for 30 min. A THF (10 mL) solution of CH3I (6.2 g, 44.0 mmol) was added dropwise at -78°C in dry ice ethanol, and the mixture was stirred at 0°C for 1 h after the addition. TLC [developing solvent PE: EA (10:1)] showed that the raw material was completely reacted. The mixture was quenched with water (50 mL) and extracted with ethyl acetate (1×50 mL). The organic phase was washed with saturated ammonium chloride solution, dried over anhydrous Na2SO4, and concentrated to obtain 10.62 g of yellow liquid methyl 2-(4-bromophenyl)propionate with a yield of 100%, without further purification. 1 H NMR (400MHz, CDCl3) δ: 7.49 (d, J = 8.2Hz, 2H), 7.22 (d, J = 8.3Hz, 2H), 3.73 (m, 1H), 3.71 (s, 3H), 1.53 (d, J = 7.1Hz, 3H); 13 C NMR (400MHz, CDCl3) δ: 174.5, 139.5, 131.7, 129.3, 121.1, 52.1, 44.9, 18.4.

[0059] Example 3: Synthesis of 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propanoate (V)

[0060] 2-(4-bromophenyl)propionic acid methyl ester (1.26 g, 5.2 mmol) was placed in a 250 mL dry three-necked bottle, palladium acetate (58 mg, 0.26 mmol), 10% tri-tert-butylphosphine n-pentane solution (0.52 g, 0.26 mmol), dicyclohexylmethylamine (2.54 g, 13 mmol), α-methylenecyclopentanone (0.65 g, 6.7 mmol), and 10 mL of dry dioxane were added. N2 was replaced, and the reaction mixture was stirred at 50°C for 17 h, TLC [developing solvent PE: EA (5:1)]. Water (30 mL) was added, and extracted with ethyl acetate (2×30 mL). The organic layer solution was dried over anhydrous Na2SO4, and purified by column chromatography to obtain compound (V) 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propionic acid ester 0.67 g of light yellow liquid, with a yield of 51%. 1H NMR(400MHz, CDCl3)δ:7.92(d,J=8.8Hz,1H),7.47(d,J=8.4Hz,2H),7.20(t,J=8.4Hz,2H),3.70-3.74 (m,1H),3.69(s,3H),2.01-1.92(m,2H),1.85-1.70(m,2H),1.68-1.60(m,2H),1.52(d,J=7.2Hz,3H); 13 C NMR (400MHz, CDCl3) δ: 196.9, 174.5, 159.0, 139.5, 131.8, 129.8, 129.2, 128.9, 127.6, 52.1, 44.9, 36.5, 29.4, 24.7, 18.5.

[0061] Example 4: Synthesis of 2-(4-((2-oxocyclopentyl)methyl)phenyl)propanoate (VI)

[0062] Add 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propionate (2.58 g, 10.0 mmol), ethanol (20 mL), and 10% Pd / C (0.13 g) to the reaction flask, and carry out hydrogenation reaction at 20°C under normal pressure for 20 h. Filter and recover Pd / C. Concentrate under reduced pressure to obtain 2.52 g of 2-(4-((2-oxocyclopentyl)methyl)phenyl)propionate as a colorless oil, with a yield of 97%. 1 H NMR (400MHz, CDCl3) δ: 7.22 (d, J = 8.4Hz, 2H), 7.12 (d, J = 8.0Hz, 2H), 3.69-3.74 (m, 1H), 3.68 (s, 3H), 3.15 (dd, J = 10.0, 2.5Hz, 1H), 2.5 0~2.54(m,1H),2.30~2.38(m,2H),2.08~2.15(m,2H),1.97~2.02(m,1H),1.70~1.76(m,1H),1.53~1.61(m,1H),1.49(d,J=7.2Hz,3H). 13 C NMR(400MHz, CDCl3)δ:13C NMR (126MHz, CDCl3) δ220.2,175.1,138.9,138.4,129.1,127.5,77.3,77.1,76.8,52.0,51.0,45.0,38.2,35.2,29.3,20.6,18.6.

[0063] Example 5: Synthesis of Loxoprofen Sodium (I)

[0064] Add compound (VI) (2.46 g, 10 mmol), acetone (20 mL) and water (2 mL) to the reaction flask, and slowly drop sodium hydroxide solution (prepared from 0.4 g NaOH solid and 0.5 mL water) at 20°C. Continue stirring for 3 h. Filter and dry to obtain 2.8 g of loxoprofen sodium, with a yield of 92%, mp 196-198°C, and HPLC purity of 99.74%. 1 H NMR(400MHz,D2O)δ:7.18(d,J=8.0Hz,2H),7.12(d,J=8.0Hz,2H),3.56(q,J=7.5Hz,1H),2.92-3.05(m,1H),2.43~2.55(m, 2H), 2.25~2.28(m,1H), 2.05~2.12(m,1H), 1.82~1.95(m,2H), 1.62~1.70(m,1H), 1.47~1.56(m,1H), 1.31(d,J=7.2Hz,3H).

[0065] The above description is only a preferred embodiment of the present invention, and therefore cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the specification should still fall within the scope of the present invention.

Claims

1. A synthetic method for loxoprofen sodium, characterized in that: The steps include: (a) Cyclopentanone, paraformaldehyde, and amine undergo a methylene reaction at the α-position of the ketone under acidic conditions to generate 2-methylenecyclopentanone (II). (b) 4-halogenophenylacetic acid ester (III) reacts with iodomethane in the presence of a base to generate 2-(4-halogenophenyl) propionic acid ester (IV). (c) Compound (II) and compound (IV) undergo Heck coupling reaction in the presence of a transition metal catalyst, a phosphine ligand and a base to obtain 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propanoate (V), (d) Compound (V) is subjected to catalytic hydrogenation to obtain 2-(4-((2-oxocyclopentyl)methyl)phenyl)propionate (VI), (e) Compound (VI) is salified in an aqueous solution of NaOH to obtain loxoprofen sodium (I), In the above formulae, X is Cl, Br or I, and R is methyl or ethyl.

2. the synthetic method of loxoprofen sodium according to claim 1, is characterized in that: In the step (a), the reaction for preparing compound (II) is carried out under acidic conditions, the acid used is selected from at least one of acetic acid, formic acid, hydrochloric acid, sulfuric acid, trichloroacetic acid or trifluoroacetic acid, and the amount of the acid used is 1.0 to 2.0 equivalents of cyclopentanone; the reaction for preparing compound (II) is carried out in the presence of an amine, the amine used is selected from at least one of methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, diisopropylamine, methylethylamine, methylisopropylamine or ethylisopropylamine, and the amount of the amine used is 1.0 to 2.0 equivalents of cyclopentanone.

3. The synthetic method of loxoprofen sodium according to claim 1, wherein: In the step (b), the reaction for preparing compound (IV) is carried out under the action of a base, the base used is selected from lithium diisopropylamide, n-butyl lithium or tert-butyl lithium, and the amount of the base used is 1.0 to 1.3 equivalents of compound (III).

4. The synthetic method of loxoprofen sodium according to claim 1, wherein: In the step (c), the reaction for preparing compound (V) is carried out under the action of a transition metal catalyst, and the transition metal catalyst used is selected from at least one of palladium acetate, palladium chloride, tris(dibenzylideneacetone)dipalladium, di(dibenzylideneacetone)palladium or tetrakis(triphenylphosphine)palladium.

5. The synthetic method of loxoprofen sodium according to claim 1, characterized in that; In the step (c), the reaction for preparing compound (V) requires the use of a phosphine ligand, and the phosphine ligand used is selected from at least one of triphenylphosphine, tri-tert-butylphosphine, tri-o-tolylphosphine, tri(2-furyl)phosphine, 1,4-bis(diphenylphosphino)butane or 1,1'-bis(diphenylphosphino)ferrocene.

6. The method for synthesizing loxoprofen sodium according to claim 1, characterized in that; In the step (c), the reaction for preparing compound (V) is carried out in a solvent, and the solvent used is selected from at least one of tetrahydrofuran, acetonitrile, toluene, dioxane or N,N-dimethylformamide; the reaction for preparing compound (V) is carried out under the action of a base, and the base used is selected from at least one of triethylamine, sodium bicarbonate, sodium carbonate, pyridine, triethylamine, dicyclohexylmethylamine, diisopropylethylamine, tri-n-propylamine or sodium acetate; the reaction temperature for preparing compound (V) from compound (II) and compound (IV) is 20 to 80°C.

7. The synthetic method of loxoprofen sodium according to claim 1, wherein: In the step (d), the reaction for preparing compound (VI) is carried out under the action of palladium carbon, platinum carbon or Raney nickel catalyst; the reaction for preparing compound (VI) from compound (V) is carried out in a solvent, and the solvent used is selected from at least one of water, methanol, ethanol, isopropanol, tetrahydrofuran or acetic acid; the reaction temperature for preparing compound (VI) from compound (V) is 0 to 50°C.

8. The synthetic method of loxoprofen sodium according to claim 1, wherein: In the step (e), the reaction for preparing the compound loxoprofen sodium (I) is carried out in a mixed solvent of water and acetone; the reaction for preparing loxoprofen sodium (I) from the compound (VI) is carried out in the presence of NaOH, and the amount of NaOH used is 0.8 to 1.2 equivalents of the compound (VI); The reaction temperature for preparing loxoprofen sodium (I) from compound (VI) is 0 to 50°C.

9. The compound 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propionate, the structural formula of which is shown below: R is methyl or ethyl.

10. A method for synthesizing the compound according to claim 9, characterized in that: The steps include: (a) Cyclopentanone, paraformaldehyde, and amine undergo a methylene reaction at the α-position of the ketone under acidic conditions to generate 2-methylenecyclopentanone (II). (b) 4-halogenophenylacetic acid ester (III) reacts with iodomethane in the presence of a base to generate 2-(4-halogenophenyl) propionic acid ester (IV). (c) Compound (II) and compound (IV) undergo Heck coupling reaction in the presence of a transition metal catalyst, a phosphine ligand and a base to obtain 2-(4-((5-oxocyclopent-1-enyl)methyl)phenyl)propanoate (V),

Citation Information

Cited By

  • Method for synthesizing loxoprofen sodium by using resin catalyst

    CN119822949A

  • Green synthesis process of non-steroidal loxoprofen sodium

    CN120864976A